News from sanofi A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 09, 2019, 17:00 ET New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder

The New England Journal of Medicine (NEJM) today published positive results of the Phase 3 trial of Cablivi® (caplacizumab) in adults with acquired...

Dec 18, 2018, 16:30 ET Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq

Sanofi today announced that it will be transferring the listing of its American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to...

Nov 13, 2018, 22:20 ET Sanofi holds China Health Road Symposium at CIIE

At the first China International Import Expo, Sanofi, the world's leading healthcare company, said during the China Health Road Symposium, that with...

Nov 11, 2018, 08:15 ET ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) Injection was associated with fewer deaths from any cause

New analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart Association (AHA) Scientific Sessions...

Nov 07, 2018, 17:00 ET New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial

The New England Journal of Medicine (NEJM) today published positive detailed results of the 18,924-patient ODYSSEY OUTCOMES trial. The trial met its...

Nov 06, 2018, 08:00 ET FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis

The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent®...
Sanofi expands Insulins VALyou Savings Program, helping more people living with diabetes

Nov 01, 2018, 07:57 ET Sanofi expands Insulins VALyou Savings Program, helping more people living with diabetes

Sanofi has expanded its access program for people living with diabetes to include all Sanofi insulins*, helping patients get the insulin they need at ...

Oct 31, 2018, 08:00 ET Sanofi Q3 2018 Performance Confirms Return to Growth

Sanofi (NYSE: SNY; EURONEXT: SAN) Q3 2018 Change Change at CER 9M 2018 Change Change at CER IFRS net sales reported €9,392m +3.7% +6.3% €25,466m...

Oct 30, 2018, 17:12 ET FDA grants priority review for Sanofi's dengue vaccine candidate

The United States Food and Drug Administration (FDA) has accepted a Biologics License Application for Sanofi Pasteur's dengue vaccine. The dengue...

Oct 26, 2018, 08:00 ET Research in Polycystic Kidney Disease Takes an Important Step Forward

Autosomal dominant polycystic kidney disease (ADPKD) is a devastating rare genetic kidney condition that leads to the growth of numerous cysts in the ...

Oct 23, 2018, 13:03 ET Breakthroughs in Breast Cancer Research

October is breast cancer awareness month, a time when thousands of people around the world participate in events aimed at supporting breast cancer...

Oct 19, 2018, 17:55 ET FDA approves asthma indication for Dupixent® (dupilumab)

Sanofi (EURONEXT: SAN) (NYSE: SNY) The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in...

Oct 16, 2018, 08:00 ET Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

Two pivotal Phase 3 placebo-controlled trials evaluating Dupixent® (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with...

Oct 15, 2018, 07:00 ET Shining a Light on Diagnosis for Rare Genetic Disease Patients

Patients with rare genetic diseases can face a difficult path to a proper diagnosis. Because there is a lower awareness of these diseases and they...

Oct 11, 2018, 10:00 ET What to Do When You Can't Afford Your Chronic Disease Medication

If you find yourself spending more on health care than ever, you're not alone. According to US government figures, out of pocket costs for many...

Oct 09, 2018, 09:00 ET Keeping Women In STEM Careers: Looking to Data For Answers

Companies across industries from IT to biopharma have long emphasized the importance of recruiting and maintaining women in jobs in the so-called...

Sep 28, 2018, 16:40 ET FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma

The U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous...

Sep 25, 2018, 09:00 ET Sanofi US Named to Working Mother 2018 "100 Best Companies" List

Working Mother has named Sanofi US as one of the top 100 companies for working mothers. The 2018 Working Mother "100 Best Company" list celebrates...

Sep 12, 2018, 08:00 ET FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License...

Sep 03, 2018, 08:00 ET Cablivi™ (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

(EURONEXT: SAN) (NYSE: SNY) -- The European Commission has granted marketing authorization for Cablivi™ (caplacizumab) for the treatment of adults...

Jul 31, 2018, 07:59 ET Q2 2018 Performance Positions Sanofi for New Growth Phase

Sanofi (NYSE: SNY; EURONEXT: SAN) Q2 2018 Change Change at CER H1 2018 Change Change at CER IFRS net sales reported €8,176m -5.7% +0.1% €16,074m...
Sanofi Ships First Flu Vaccines for 2018-2019 Season

Jul 30, 2018, 13:37 ET Sanofi Ships First Flu Vaccines for 2018-2019 Season

Sanofi Pasteur, the vaccine division of Sanofi (EURONEXT: SAN) (NYSE: SNY), today shipped the first of its nearly 70 million flu vaccine doses to...

Jul 02, 2018, 06:00 ET Sanofi to further accelerate its scientific presence with the opening of a Global R&D Operations Hub in Chengdu, China

Sanofi (EURONEXT: SAN) (NYSE: SNY) is launching a Global R&D Operations Hub with a specialized focus on digitalization and big data analysis in...

Jun 25, 2018, 08:01 ET Sanofi presents results from the first head-to-head study comparing Toujeo® to insulin degludec

Sanofi (NYSE: SNY; EURONEXT: SAN) presented positive non-inferiority results of the BRIGHT study comparing its long-acting insulin Toujeo® to insulin ...

Jun 04, 2018, 02:15 ET New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma

The New England Journal of Medicine (NEJM) today published pivotal data from two trials evaluating cemiplimab in advanced cutaneous squamous cell...